Retinoic acid
Information
- Drug Name
- Retinoic acid
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A combination of retinoic acid (RA) and HDACI acte... | HDAC9 | HDAC9 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| HDAC inhibits the expression of RAR | HDAC9 | HDAC9 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| SOX9 is often downregulated in melanoma. Melanoma ... | SOX9 | SOX9 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| PRAME inhibits the RAR (retinoic acid receptor) pa... | PRAME | PRAME UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04417348 | Completed | N/A | Opsin Receptors in Melasma | January 31, 2019 | December 15, 2019 |
| NCT03392623 | Completed | Early Phase 1 | DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. | January 1, 2015 | December 1, 2016 |
| NCT02497833 | Completed | Early Phase 1 | Retinoic Acid Supplementation and Subjects With Hypercholesterolemia | November 2014 | May 2015 |
| NCT03491267 | Enrolling by invitation | Early Phase 1 | Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis | January 1, 2018 | December 31, 2025 |
| NCT00533169 | Terminated | Phase 1 | ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma | September 2007 | February 2011 |
| NCT02641782 | Terminated | Phase 2 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial | November 2015 | January 30, 2017 |
| NCT05281965 | Unknown status | Early Phase 1 | A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome | April 1, 2022 | June 1, 2024 |
| NCT01275274 | Withdrawn | Phase 2 | Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens | January 2012 | December 2013 |
| NCT01048086 | Withdrawn | Phase 2 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | June 2009 | November 2013 |